Paxlovid Doesn't Increase Risk for Rebound COVID Infection: Study
The findings offer clarity amid concerns that the use of Paxlovid increased the risk for COVID-19 rebound.
Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The findings offer clarity amid concerns that the use of Paxlovid increased the risk for COVID-19 rebound.
The National Institutes of Health said on Wednesday that it had started a clinical trial to evaluate Shionogi's experimental oral antiviral drug to treat COVID-19.
The research team observed a potential decrease in effectiveness over time, and one author called for continued monitoring.
Clinicians should be "aware that the infants of pregnant people with HCV may have a high rate of need for higher-level pediatric care."
Patients with rheumatic disease and SARS-CoV-2 infection who received outpatient treatment fared better than similar patients who did not receive treatment, but COVID-19 rebound was not infrequent in patients who received outpatient treatment.